Skip to main content

Market Overview

Exceeding Expectations, Chemours Shares Upgraded At UBS

Exceeding Expectations, Chemours Shares Upgraded At UBS

UBS upgraded shares of Chemours Co (NYSE: CC) following better-than-expected second-quarter results, helped by cost cutting and fluoroproducts growth.

Analysts John Roberts and Edlain Rodriguez said their prior concerns regarding Chemours' ability to deliver cost savings, fluoroproducts growth and liabilities have been disproved by the thumping performance.

UBS said the company continues to benefit from TiO2 price increases and cost savings following the bottom in the first quarter. The company expects price increases of 15 percent for 2017 and 10 percent for 2018, although expecting prices to moderate after 2017. TiO2 account for about 55 percent of the 2018 EBITDA.

See also: The Simple Case For Being A Chemours Bull

Additionally, the firm said fluoroproducts, accounting for about 40 percent of 2018 EBITA, continue to ramp to nextgen refrigerants. The firm believes Opteon HFO would be a key growth driver, with the company investing to triple capacity by the end of next year.

The firm noted that the company raised its EBITDA guidance for the second half from $640 million to about $650 million to $750 million. Accordingly, the firm sees a more balanced risk/reward going forward.

Consequently, UBS raised its EBITDA estimates for 2017 from $1.25 billion to $1.36 billion, for 2018 from $1.47 billion to $1.62 billion and for 2019 from $1.45 billion to $1.65 billion.

As such, UBS upgraded shares of Chemours from Sell to Neutral and raised its price target from $36 to $50, as it moved its valuation base to 2018 to reflect higher confidence in the growth outlook.

At the time of writing, Chemours is advancing 1.60 percent to $50.10.

Latest Ratings for CC

Feb 2021Morgan StanleyMaintainsEqual-Weight
Jan 2021RBC CapitalUpgradesSector PerformOutperform
Dec 2020Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for CC
View the Latest Analyst Ratings


Related Articles (CC)

View Comments and Join the Discussion!

Posted-In: John Roberts and Edlain Rodriguez UBSAnalyst Color Upgrades Price Target Analyst Ratings Tech Best of Benzinga

Latest Ratings

ACVAJefferiesInitiates Coverage On45.0
DSEYJP MorganInitiates Coverage On17.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at